The NETTER‐2 trial clearly demonstrated clinically meaningful activity and significant PFS superiority of PRRT versus high‐dose SSA (control arm: 60 mg octreotide intramuscularly every 4 weeks in the first‐line setting) as a first‐line treatment option for patients with NET G3 SRI‐positive tumours and Ki‐67 <55%. The gene discussed is MKI67; the disease is neoplasm.